PharmaCyte Biotech, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2021, with fiscal 2020 comparisons. The request labels the period “2020 Q4,” but this filing is an annual report for FY2021, not a standalone quarterly report. Share and per-share figures reflect the filing’s retroactive 1-for-1,500 reverse stock split.
Business context and development status
PharmaCyte is a pre-revenue biotechnology company developing cellular therapies using its Cell-in-a-Box encapsulation technology. Its lead program combines encapsulated cells intended to activate the chemotherapy prodrug ifosfamide near locally advanced, inoperable pancreatic tumors (LAPC).
The FDA placed the company’s September 2020 IND for a planned Phase 2b LAPC trial on clinical hold in October 2020. The proposed trial would enroll approximately 100 patients and compare CypCaps plus low-dose ifosfamide with specified radiation-based control treatments. The primary endpoint is progression-free survival; the study has not begun.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3,622,981 | $3,826,395 |
| Research and development expense | $916,249 | $301,221 |
| Loss from operations | $(3,622,981) | $(3,826,395) |
| Net loss | $(3,551,236) | $(3,826,888) |
| Basic and diluted loss per share | $(2.45) | $(4.23) |
| Net cash used in operating activities | $(3,330,889) | $(2,338,373) |
| Cash at year-end | $2,202,106 | $894,861 |
| Total assets | $7,404,229 | $6,166,638 |
| Total liabilities | $724,778 | $1,077,680 |
Margins: Not meaningful because the company reported no revenue. The filing reports no investing cash flows in either year. Financing provided $4,636,807 in FY2021, primarily from common-stock sales, versus $2,725,848 in FY2020. The PPP loan and accrued interest were forgiven in FY2021; no PPP balance remained at year-end.
The company reported a $107.4 million accumulated deficit and stated that substantial additional capital is needed. Management identified substantial doubt about the ability to continue as a going concern, while concluding its financing plans alleviate that doubt. It estimated cash expenditures at approximately $200,000 per month and projected funding through August 31, 2022, assuming cash on hand, potential share sales and the planned offering.
Changes, outlook, risks and unusual items
- Operating expenses fell about $203,000 year over year, while R&D expense rose about $615,000, or 204%, as work shifted to the IND and FDA hold response. Lower compensation and general and administrative expenses more than offset higher R&D and legal and professional costs.
- Net loss narrowed by about $276,000. FY2021 other income included a $75,979 gain from forgiveness of the $75,200 PPP principal and accrued interest.
- The company completed reported CypCaps stability testing through 12 months, with the product said to have passed specified tests. The stability study continues. The filing references both -80°C and -180°C storage in different sections; the precise conditions should be checked against the underlying study documentation.
- To address the hold, the FDA requested additional preclinical work and information, including genetic sequencing and stability data, manufacturing and release details, device compatibility, biocompatibility testing, product comparability, and a large-animal study. Management said these efforts were in progress; the filing reports no subsequent FDA communication on the hold.
- COVID-19 caused delays to studies and assays conducted through overseas providers and disrupted supply chains. Further delays could affect any future trial’s start, enrollment, conduct and data integrity.
- Cannabinoid, malignant-ascites and diabetes programs were not receiving further development funding pending progress on the LAPC program, validation of the platform in that trial, and sufficient financing. The diabetes program had encountered instability in the Melligen cells and results below expectations.
- On August 9, 2021, after fiscal year-end, the company entered an underwriting agreement for an offering expected to generate $15 million gross, before expenses, comprising common shares, pre-funded warrants and common warrants. Full exercise of the underwriter’s option could raise expected gross proceeds to approximately $17.25 million. This was subsequent to year-end and should not be treated as FY2021 cash.
- The company reported material weaknesses in financial reporting controls: insufficient segregation of CFO duties and inadequate IT controls and documentation. Disclosure controls were deemed ineffective as of April 30, 2021. A previously reported weakness concerning procedures and contract review was described as remediated.
- The independent auditor gave an unqualified opinion on the financial statements but identified going concern as a critical audit matter. The audit did not include an opinion on internal-control effectiveness.
Important facts for investors to verify
- Whether all FDA hold items have been completed and submitted, and whether the FDA has lifted the clinical hold or requested further work.
- Whether the August 2021 offering closed as planned, its net proceeds after discounts and expenses, and the resulting fully diluted share count and warrant overhang.
- Cash runway assumptions and actual monthly cash burn, given continuing operating losses, no revenue and the company’s dependence on external financing.
- Underlying CypCaps stability results, including the reported storage temperature, test methods, comparability between product generations, and outcomes of remaining preclinical studies.
- Progress on remediation of internal-control weaknesses and any subsequent changes to the company’s control assessment.
- The company’s reliance on Austrianova and other third parties, related-party payments, manufacturing capacity, and the status and scope of its licensed and pending intellectual-property rights.
- Whether historical European trial results from 1998–2000 are accepted by the FDA and can support the proposed Phase 2b program; those small, non-statistically significant studies do not establish efficacy.